ESPR
Esperion Therapeutics IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$491.64M
P/E Ratio
—
EPS
$-0.11
Beta
1.17
52W High
$4.17
52W Low
$0.69
50-Day MA
$2.60
200-Day MA
$2.78
Dividend Yield
—
Profit Margin
-5.63%
Forward P/E
4.64
PEG Ratio
-4.78
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
Fundamentals
| Revenue (TTM) | $403.13M |
| Gross Profit (TTM) | $226.06M |
| EBITDA | $60.38M |
| Operating Margin | 50.60% |
| Return on Equity | -260.80% |
| Return on Assets | 9.31% |
| Revenue/Share (TTM) | $1.94 |
| Book Value | $-1.23 |
| Price-to-Book | 98.42 |
| Price-to-Sales (TTM) | 1.22 |
| EV/Revenue | 1.429 |
| EV/EBITDA | 9.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 143.70% |
| Shares Outstanding | $257.40M |
| Float | $254.57M |
| % Insiders | 0.68% |
| % Institutions | 63.27% |
Historical Volatility
HV 10-Day
40.73%
HV 20-Day
61.31%
HV 30-Day
64.65%
HV 60-Day
71.28%
HV Rank
18.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($6.74 target)
3
Strong Buy2
Buy1
Hold1
Strong SellData last updated: 4/30/2026